Problem Solved: Novel mTOR 1/2 Inhibitor Available for Licensing

Our client has a Preclinical, highly selective mTOR 1/2 inhibitor available for licensing.
This compound is a truly selective inhibitor of both mTORC1 and mTORC2, without PI3K activity or toxicity.
With an excellent projected safety profile & oral administration, a number of indications within and outside oncology are possible.
For more information, contact us via email by clicking on the link below:

SaveSave

Google Plus   Facebook   Twitter
Powered By : Supra International Inc.